|
[1]
|
李晓宇, 顾向应. 我国生育力现状及面临的挑战[J]. 中国计划生育和妇产科, 2020, 12(1): 3-6, 97-98.
|
|
[2]
|
Liang, S., Chen, Y., Wang, Q., et al. (2021) Prevalence and Associated Factors of Infertility among 20-49 Year Old Women in Henan Province, China. Reproductive Health, 18, Article No. 254. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Wang, R., Li, W., Bordewijk, E.M., et al. (2019) First-Line Ov-ulation Induction for Polycystic Ovary Syndrome: An Individual Participant Data Meta-Analysis. Human Reproduction Update, 25, 717-732. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Shrivastava, S. and Conigliaro, R.L. (2023) Polycystic Ovarian Syn-drome. Medical Clinics of North America, 107, 227- 234. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Skiba, M.A., Islam, R.M., Bell, R.J. and Davis, S.R. (2018) Understanding Variation in Prevalence Estimates of Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Human Reproduction Update, 24, 694-709. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Safiri, S., Noori, M., Nejadghaderi, S.A., et al. (2022) Prevalence, Incidence and Years Lived with Disability Due to Polycystic Ovary Syndrome in 204 Countries and Territories, 1990-2019. Human Reproduction, 37, 1919-1931. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Yang, R., Li, Q., Zhou, Z., et al. (2022) Changes in the Prevalence of Polycystic Ovary Syndrome in China over the Past Decade. The Lancet Regional Health—Western Pacific, 25, Article ID: 100494. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Vanhise, K., Wang, E.T., Norris, K., et al. (2023) Racial and Ethnic Disparities in Polycystic Ovary Syndrome. Fertility and Sterility, 119, 348-354. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Abdalla, M., Deshmukh, H., Atkin, S.L. and Sathyapalan, T. (2020) MiRNAs as a Novel Clinical Biomarker and Therapeutic Targets in Polycystic Ovary Syndrome (PCOS): A Re-view. Life Sciences, 259, Article ID: 118174. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Wang, J., Wu, D., Guo, H., et al. (2019) Hyperandrogenemia and Insulin Resistance: The Chief Culprit of Polycystic Ovary Syndrome. Life Sciences, 236, Article ID: 116940. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Balen, A.H., Morley, L.C., Misso, M., et al. (2016) The Manage-ment of Anovulatory Infertility in Women with Polycystic Ovary Syndrome: An Analysis of the Evidence to Support the Development of Global WHO Guidance. Human Reproduction Update, 22, 687-708. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Legro, R.S., Castracane, V.D. and Kauffman, R.P. (2004) Detecting Insulin Resistance in Polycystic Ovary Syndrome: Purposes and Pitfalls. Obstetrical & Gynecological Survey, 59, 141-154. [Google Scholar] [CrossRef]
|
|
[13]
|
Crespo, R.P., Bachega, T., Mendonça, B.B., et al. (2018) An Update of Genetic Basis of PCOS Pathogenesis. Archives of Endocrinology and Metabolis, 62, 352-361. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Sanchez-Garrido, M.A. and Tena-Sempere, M. (2020) Meta-bolic Dysfunction in Polycystic Ovary Syndrome: Pathogenic Role of Androgen Excess and Potential Therapeutic Strate-gies. Molecular Metabolism, 35, Article ID: 100937. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Lonardo, M.S., Cacciapuoti, N., Guida, B., et al. (2024) Hypo-thalamic-Ovarian Axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Op-tions for the Management of Metabolic and Inflammatory Aspects. Current Obesity Reports. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Nestler, J.E., Powers, L.P., Matt, D.W., et al. (1991) A Direct Effect of Hyperinsulinemia on Serum Sex Hormone- Binding Globulin Levels in Obese Women with the Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 72, 83-89. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Franks, S., Stark, J. and Hardy, K. (2008) Follicle Dynamics and Anov-ulation in Polycystic Ovary Syndrome. Human Reproduction Update, 14, 367-378. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Sam, S. and Ehrmann, D.A. (2017) Metformin Therapy for the Re-productive and Metabolic Consequences of Polycystic Ovary Syndrome. Diabetologia, 60, 1656-1661. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Eng, P.C., Phylactou, M., Qayum, A., et al. (2023) Obesi-ty-Related Hypogonadism in Women. Endocrine Reviews. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Wang, F.F., Wu, Y., Zhu, Y.H., et al. (2018) Pharmacologic Therapy to Induce Weight Loss in Women Who Have Obesity/Overweight with Polycystic Ovary Syndrome: A Systematic Re-view and Network Meta-Analysis. Obesity Reviews, 19, 1424-1445. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Glueck, C.J. and Goldenberg, N. (2019) Characteristics of Obesity in Polycystic Ovary Syndrome: Etiology, Treatment, and Ge-netics. Metabolism, 92, 108-120. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Arya, S., Hansen, K.R., Peck, J.D., et al. (2021) Metabolic Syndrome in Obesity: Treatment Success and Adverse Pregnancy Outcomes with Ovulation Induction in Polycystic Ovary Syndrome. American Journal of Obstetrics and Gynecology, 225, 280.E1-280.E11. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Liu, Q., Zhu, Z., Kraft, P., et al. (2022) Genomic Correlation, Shared Loci, and Causal Relationship between Obesity and Polycystic Ovary Syndrome: A Large-Scale Genome-Wide Cross-Trait Analysis. BMC Medicine, 20, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Rudnicka, E., Suchta, K., Grymowicz, M., et al. (2021) Chronic Low Grade Inflammation in Pathogenesis of PCOS. International Journal of Molecular Sciences, 22, Article 3789. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Siddiqui, S., Mateen, S., Ahmad, R., et al. (2022) A Brief Insight into the Etiology, Genetics, and Immunology of Polycystic Ovarian Syndrome (PCOS). Journal of Assisted Reproduction and Genetics, 39, 2439-2473. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Patel, S. (2018) Polycystic Ovary Syndrome (PCOS), an In-flammatory, Systemic, Lifestyle Endocrinopathy. The Journal of Steroid Biochemistry and Molecular Biology, 182, 27-36. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Abraham Gnanadass, S., Divakar Prabhu, Y. and Valsala Gopalakrishnan, A. (2021) Association of Metabolic and Inflammatory Markers with Polycystic Ovarian Syndrome (PCOS): An Update. Archives of Gynecology and Obstetrics, 303, 631-643. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Riestenberg, C., Jagasia, A., Markovic, D., et al. (2022) Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences. The Journal of Clinical Endocrinology & Metabolism, 107, 575-585. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Haase, C.L., Varbo, A., Laursen, P.N., et al. (2023) Association be-tween Body Mass Index, Weight Loss and the Chance of Pregnancy in Women with Polycystic Ovary Syndrome and Overweight Or Obesity: A Retrospective Cohort Study in the UK. Human Reproduction, 38, 471-481. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Cowan, S., Lim, S., Alycia, C., et al. (2023) Lifestyle Management in Polycystic Ovary Syndrome—Beyond Diet and Physical Activity. BMC Endocrine Disorders, 23, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Costello, M.F., Misso, M.L., Balen, A., et al. (2019) Evidence Summaries and Recommendations from the International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome: Assessment and Treatment of Infertility. Human Reproduction Open, 2019, Hoy021. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Li, M., Chi, X., Wang, Y., et al. (2022) Trends in Insulin Resistance: Insights into Mechanisms and Therapeutic Strategy. Signal Transduction and Targeted Therapy, 7, Article No. 216. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Lim, S.S., Hutchison, S.K., Van, Ryswyk, E., et al. (2019) Life-style Changes in Women with Polycystic Ovary Syndrome. Cochrane Database of Systematic Reviews, 3, CD007506. [Google Scholar] [CrossRef]
|
|
[34]
|
Teede, H.J., Misso, M.L., Costello, M.F., et al. (2018) Recommendations from the International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction, 33, 1602-1618. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Teal, S. and Edelman, A. (2021) Contraception Selection, Effective-ness, and Adverse Effects: A Review. JAMA, 326, 2507-2518. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Foda, A.A., Foda, E.A., El-Negeri, M.A. and El-Said, Z.H. (2019) Serum Chemerin Levels in Polycystic Ovary Syndrome af-ter Metformin Therapy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13, 1309-1315. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Glintborg, D., Hermann, A.P., Andersen, M., et al. (2006) Effect of Pioglitazone on Glucose Metabolism and Luteinizing Hormone Secretion in Women with Polycystic Ovary Syndrome. Fertility and Sterility, 86, 385-397. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Elkind-Hirsch, K.E., Chappell, N., Shaler, D., et al. (2022) Li-raglutide 3 Mg on Weight, Body Composition, and Hormonal and Metabolic Parameters in Women with Obesity and Polycystic Ovary Syndrome: A Randomized Placebo- Controlled-Phase 3 Study. Fertility and Sterility, 118, 371-381. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Vaduganathan, M., Docherty, K.F., Claggett, B.L., et al. (2022) SGLT-2 Inhibitors in Patients with Heart Failure: A Comprehensive Meta-Analysis of Five Randomised Controlled Tri-als. Lancet, 400, 757-767. [Google Scholar] [CrossRef]
|
|
[40]
|
Sen, T. and Heerspink, H.J.L. (2021) A Kidney Perspective on the Mechanism of Action of Sodium Glucose Co-Trans- porter 2 Inhibitors. Cell Metabolism, 33, 732-739. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Sabolic, I., Vrhovac, I., Eror, D.B., et al. (2012) Expression of Na+-D-Glucose Cotransporter SGLT2 in Rodents Is Kidney-Specific and Exhibits Sex and Species Differences. Ameri-can Journal of Physiology-Cell Physiology, 302, C1174-C1188. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Pruett, J.E., Torres Fernandez, E.D., Everman, S.J., et al. (2021) Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome. Interna-tional Journal of Molecular Sciences, 22, Article 2576. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Xie, L.L. and Xia, W.F. (2022) Characteristics and Molecular Mechanisms through Which SGLT2 Inhibitors Improve Metabolic Dis-eases: A Mechanism Review. Life Sciences, 300, Article ID: 120543. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Wei, D., Liao, L., Wang, H., et al. (2020) Canagliflozin Ameliorates Obesity by Improving Mitochondrial Function and Fatty Acid Oxidation Via PPARα in Vivo and in Vitro. Life Sciences, 247, Article ID: 117414. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Elkind-Hirsch, K.E., Chappell, N., Seidemann, E., et al. (2021) Ex-enatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 106, 3019-3033. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Zhang, J., Xing, C., Cheng, X., et al. (2022) Canagliflozin Combined with Metformin versus Metformin Monotherapy for Endocrine and Metabolic Profiles in Overweight and Obese Women with Polycystic Ovary Syndrome: A Single- Center, Open-Labeled Prospective Randomized Controlled Trial. Frontiers in Endocrinology, 13, Article 1003238. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Javed, Z., Papageorgiou, M., Deshmukh, H., et al. (2019) Effects of Empagliflozin on Metabolic Parameters in Polycystic Ovary Syndrome: A Randomized Controlled Study. Clinical Endocrinology, 90, 805-813. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
O’brien, T.P., Jenkins, E.C., Estes, S.K., et al. (2017) Correcting Postpran-dial Hyperglycemia in Zucker Diabetic Fatty Rats with an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle. Diabetes, 66, 1172-1184. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Han, J.H., Oh, T.J., Lee, G., et al. (2017) The Beneficial Effects of Em-pagliflozin, an SGLT2 Inhibitor, on Atherosclerosis in ApoE-/- Mice Fed A Western Diet. Diabetologia, 60, 364-376. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Op Den Kamp, Y.J.M., De Ligt, M., Dautzenberg, B., et al. (2021) Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients with Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. Diabetes Care, 44, 1334-1343. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Heerspink, H.J.L., Perco, P., Mulder, S., et al. (2019) Canagliflozin Reduces Inflammation and Fibrosis Biomarkers: A Potential Mechanism of Action for Beneficial Effects of SGLT2 Inhibitors in Diabetic Kidney Disease. Diabetologia, 62, 1154-1166. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Lee, W.C., Chau, Y.Y., Ng, H.Y., et al. (2019) Em-pagliflozin Protects HK-2 Cells from High Glucose-Mediated Injuries via a Mitochondrial Mechanism. Cells, 8, Article 1085. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Sato, T., Aizawa, Y., Yuasa, S., et al. (2020) The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-Hoc Analysis of the Previ-ous Randomized Clinical Trial. Journal of Atherosclerosis and Thrombosis, 27, 1348-1358. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Theofilis, P., Sagris, M., Oikonomou, E., et al. (2022) The Impact of SGLT2 Inhibitors on Inflammation: A Systematic Review and Meta-Analysis of Studies in Rodents. International Im-munopharmacology, 111, Article ID: 109080. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Gill, V., Kumar, V., Singh, K., et al. (2019) Advanced Glycation End Products (AGEs) May Be a Striking Link Between Modern Diet and Health. Biomolecules, 9, Article 888. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Ojima, A., Matsui, T., Nishino, Y., et al. (2015) Empagliflozin, an In-hibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Re- ceptor Axis. Hormone and Metabolic Research, 47, 686692. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Cai, M., Shao, X., Xing, F., et al. (2022) Efficacy of Canagliflozin versus Metformin in Women with Polycystic Ovary Syndrome: A Randomized, Open-Label, Noninferiority Trial. Dia-betes, Obesity and Metabolism, 24, 312-320. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Tan, S., Ignatenko, S., Wagner, F., et al. (2021) Licogliflozin versus Pla-cebo in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Phase 2 Trial. Diabetes, Obesity and Metabolism, 23, 2595-2599. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Sinha, B. and Ghosal, S. (2022) A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients with Polycystic Ovary Syndrome. Frontiers in Endocrinology, 13, Article 830401. [Google Scholar] [CrossRef] [PubMed]
|